Suppr超能文献

结缔组织病相关间质性肺炎急性加重的临床特征及预后

Clinical features and outcome of acute exacerbation of interstitial pneumonia associated with connective tissue disease.

作者信息

Toyoda Yuko, Hanibuchi Masaki, Kishi Jun, Kawano Hiroshi, Morizumi Shun, Sato Seidai, Kondo Mayo, Takikura Terumi, Tezuka Toshifumi, Goto Hisatsugu, Nishioka Yasuhiko

机构信息

Department of Respiratory Medicine and Rheumatology, Tokushima University Hospital.

出版信息

J Med Invest. 2016;63(3-4):294-9. doi: 10.2152/jmi.63.294.

Abstract

Acute exacerbation (AE) of interstitial lung disease is reported to be developed in not only idiopathic pulmonary fibrosis but also connective tissue disease-associated interstitial pneumonia (CTD-IP). As the significance of AE of CTD-IP has not been so widely recognized, its clinical feature is not fully elucidated. In the present study, we investigated the incidence, clinical features and outcome of AE of CTD-IP. We retrospectively reviewed admitted cases in our department with medical record from 2011 to 2015. Among 155 patients with CTD-IP, 10 (6.5%) cases developed AE (6 rheumatoid arthritis, 2 polymyositis/dermatomyositis, 1 systemic lupus erythematosus, 1 Sjögren syndrome), and one died of AE within 30 days. Median survival time after the onset of AE was 169 days in all 10 patients. The treatment with immunosuppressant just before AE onset might improve the prognosis of AE. The median survival time after the onset of AE was significantly longer in patients showing good response to corticosteroid compared with those with poor response to corticosteroid (805 days and 45 days, respectively) (p <0.05), suggesting that there are some cases in CTD-IP, showing the good response to corticosteroid even when AE was complicated. J. Med. Invest. 63: 294-299, August, 2016.

摘要

据报道,间质性肺疾病的急性加重(AE)不仅会在特发性肺纤维化中发生,也会在结缔组织病相关间质性肺炎(CTD-IP)中出现。由于CTD-IP的AE的重要性尚未得到广泛认可,其临床特征也未完全阐明。在本研究中,我们调查了CTD-IP的AE的发病率、临床特征和结局。我们回顾性分析了2011年至2015年我院收治的病例的病历。在155例CTD-IP患者中,10例(6.5%)发生了AE(6例类风湿关节炎,2例多发性肌炎/皮肌炎,1例系统性红斑狼疮,1例干燥综合征),1例在30天内死于AE。所有10例患者AE发作后的中位生存时间为169天。AE发作前使用免疫抑制剂治疗可能会改善AE的预后。与对皮质类固醇反应不佳的患者相比,对皮质类固醇反应良好的患者AE发作后的中位生存时间显著更长(分别为805天和45天)(p<0.05),这表明在CTD-IP中,即使并发AE,也有一些病例对皮质类固醇反应良好。《医学调查杂志》63:294 - 299,2016年8月。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验